clinical development

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.

Moleculin Biotech releases CEO update on Phase 3 MIRACLE trial evaluating Annamycin for relapsed/refractory acute myeloid leukemia, with enrollment progressing on schedule.

$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.

Can-Fite's namodenoson meets primary safety endpoint in Phase IIa pancreatic cancer trial with no new safety signals; survival data pending.

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Absci appoints Vertex Pharma veteran Dr. Ransi Somaratne as Chief Medical Officer to lead clinical development of AI-designed therapeutics, signaling execution focus.

Medidata secures top 'Luminary' AI rating from Everest Group, supporting 80% of FDA approvals with up to 37% faster patient enrollment.

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.

Tevogen Bio pursues acquisition of Sciometrix to gain Clinicus digital care platform, integrating it with its AI division to expand into healthcare services alongside biotech operations.

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.

GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.